KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis

<table>Clonogenic survival of GBM cells was significantly decreased by the combination of KML001 and TMZ or irradiation. GBM cells were seeded at 100/dish density in culture dishes and incubated for 10 days with indicated treatment. Survival fraction was demonstrated. (a) U251MG, combination with KML001 and TMZ, (b) U87MG, combination with KML001 and TMZ, (c) U251MG, combination with KML001 and irradiation, and (d) U87MG, combination with KML001 and irradiation.</table>

BioMed Research International

fig1

Figure 1

Figure 1: KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis 

Figure 1 | KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis 